DRADS Capital

Alsym Energy has developed a cost-effective rechargeable energy storage technology that does not rely on lithium or cobalt, making it suitable for applications including stationary storage, maritime shipping, and electric vehicles. The company's innovative approach utilizes readily available, non-toxic, and non-flammable materials, positioning it as a viable alternative to traditional lithium-based technologies. By delivering energy storage solutions that offer performance comparable to lithium-ion systems at a significantly lower cost, Alsym Energy aims to facilitate the global transition to decarbonization and enhance the accessibility of renewable energy solutions.

QuanticAsset develops AI-driven asset management and investment products for high-net-worth family offices and institutional investors.

Angiowave Provides shockwave therapy services intended to offer safe, comfortable treatment for men to optimize sexual performance.

The Live Green Company, founded in 2018 and based in Santiago, Chile, specializes in developing plant-based food products. The company offers a range of items, including live green burger mixes and pancake mixes. Utilizing advanced technology, The Live Green Company employs proprietary methods that combine big data, artificial intelligence, machine learning, and precision fermentation to enhance the functionality and sustainability of consumer packaged goods. This innovative approach allows the company to research and develop active functional ingredients efficiently, contributing to its mission of creating cleaner and more sustainable food options.

The Live Green Company, founded in 2018 and based in Santiago, Chile, specializes in developing plant-based food products. The company offers a range of items, including live green burger mixes and pancake mixes. Utilizing advanced technology, The Live Green Company employs proprietary methods that combine big data, artificial intelligence, machine learning, and precision fermentation to enhance the functionality and sustainability of consumer packaged goods. This innovative approach allows the company to research and develop active functional ingredients efficiently, contributing to its mission of creating cleaner and more sustainable food options.

Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.

Zammo.ai is a developer of a conversational artificial intelligence platform that enables enterprises to enhance customer engagement through voice and text communication. The platform facilitates the creation of a ChatGPT-like experience by leveraging web pages, knowledge base articles, and document repositories, streamlining the process for businesses to implement conversational AI across various channels, including telephony and social media. Zammo.ai's user-friendly and cost-effective solution allows organizations of all sizes to establish a branded presence and deploy conversational tools quickly, with minimal IT support. Additionally, Zammo.ai is committed to improving accessibility, thereby enabling individuals with disabilities to interact with businesses in a more natural and intuitive manner. The platform supports multiple languages and helps enterprises achieve their accessibility goals while broadening their customer reach. By fostering collaboration within a remote team, Zammo.ai continuously enhances its product offerings and market presence to assist clients in their digital transformation journeys.

MarvelBiome, Inc. is a biopharmaceutical company based in Woburn, Massachusetts, that specializes in leveraging microbial populations for the development of treatments for various human diseases. Founded in 2019, the company is dedicated to isolating, identifying, and characterizing these microbes to create novel therapeutic applications. By advancing biopharmaceutical technologies, MarvelBiome aims to enable researchers to improve assay methods and further explore the potential of microbial-based therapies in addressing health challenges.

ROKIT Healthcare specializes in advanced bio-printing technology, providing hardware, software, and application support for the design and creation of three-dimensional systems. The company focuses on developing custom fabrication technologies that enable hyper-personalized medical solutions for organ regeneration, specifically targeting the regeneration of skin and cartilage through surgical applications. By leveraging artificial intelligence and proprietary bio-fabrication techniques, ROKIT Healthcare aims to enhance tissue engineering and regenerative medicine, ultimately improving health outcomes and quality of life for patients. Their innovative approach allows physicians to utilize bioprinting platforms effectively, advancing research and clinical capabilities in the medical field.

Amylyx Pharmaceuticals develops innovative therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The company's primary product, AMX0035, is an investigational therapy that combines two active compounds, sodium phenylbutyrate and Taurursodiol. This fixed-dose formulation aims to address mitochondrial energy crises and the accumulation of toxic proteins in the endoplasmic reticulum, which contribute to neurological decline. In addition to ALS, Amylyx's research pipeline includes potential treatments for Wolfram syndrome and Alzheimer's disease. Founded in 2013 and based in Cambridge, Massachusetts, Amylyx Pharmaceuticals is dedicated to advancing solutions for serious brain disorders.

AZTherapies, Inc. is a biopharmaceutical company based in Boston, Massachusetts, focused on discovering, developing, and commercializing innovative therapies for neurodegenerative diseases, including Alzheimer's, stroke, ALS, and Parkinson's disease. Established in 2011, the company is advancing a clinical-stage pipeline of small molecule drugs designed to address the underlying mechanisms of these conditions, particularly neuroinflammation and the aggregation of amyloid-beta proteins. Its lead candidate, ALZT-OP1, employs a multi-modal approach to potentially halt or slow the progression of Alzheimer's disease, with the Phase 3 COGNITE trial fully enrolled. In addition to Alzheimer's, AZTherapies is also progressing treatments for cognitive impairment following strokes and other related disorders, aiming to enhance the quality of life for aging populations with limited therapeutic options.

REACT Neuro is a digital healthcare company based in Cambridge, Massachusetts, focused on advancing brain health through an artificial intelligence-driven platform. This platform includes a range of clinically validated assessments that evaluate patients' brain health using digital biomarkers. REACT Neuro offers personalized virtual reality services that incorporate eye-tracking, voice recognition, and movement analysis, enhancing the understanding of neurocognitive function. By employing multimodal neurophysiological phenotyping, the company aims to provide objective measurements of brain health, supporting healthy aging and overall wellness.

Predictus BioSciences, Inc. was incorporated in 2010 and is based in West Roxbury, Massachusetts.